Responses
Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types
Compose a Response to This Article
Other responses
No responses have been published for this article.
